Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Females aged 25-60~2. BMI 28-35 kg/m2~3. No known diagnosis of diabetes~4. No known diagnosis of coronary heart disease~5. Self-described sedentary lifestyle with minimal regular cardiovascular exercise (no more than 1 hour per week)~6. Stable weight (variation \< 3 kg within 6 months of screening visit)~7. Ability to give informed consent~8. Ability to follow verbal and written instructions~9. Use of medically approved form of contraception (monophasic oral contraception, intra uterine device, surgical sterilization or 2 combined barrier methods)~10. Nonsmoker (tobacco, marijuana)~11. Outpatient visits every 2 weeks throughout the study period are required. While most of these visits are short (15 minutes)ability to commute to the performance site in Boston, on a regular basis, is necessary.~Exclusion Criteria:~1. Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes Association criteria~2. Coronary heart disease (history of myocardial infarction or unstable angina pectoris)~3. Uncontrolled hypertension hypertension (BP \> 150/90 mmHg on or off antihypertensive medication)~4. Uncontrolled dyslipidemia (LDL \> 200 or TG \> 400 on or off lipid lowering medication)~5. Tobacco, marijuana or intravenous drug use~6. Shift workers (night shift or alternating day/night shifts)~7. Recent weight loss (\> 3 kg within 4 months of the screening visit)~8. Gastroparesis~9. Inflammatory bowel disease~10. Malignancy treated with chemotherapy within the past 3 years~11. History of pancreatitis~12. Depression requiring hospitalization or diagnosis of psychosis~13. Renal insufficiency (creatinine clearance \< 50 ml/min)~14. Transaminases \> 2x above the normal range~15. Pregnancy within 6 months of the screening visit~16. Breastfeeding~17. Failure to use medically approved contraceptive methods~18. History of an eating disorder (anorexia, bulimia or laxative abuse)~19. History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling)~20. New diagnosis of hypo or hyperthyroidism within 1 year of screening visit~21. Previous participation in a clinical study with exenatide~22. Presence or history of allergic reaction to multiple drugs

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Exenatide First (Type: PLACEBO_COMPARATOR): Started on Exenatide, 3 week washout, start placebo
- Placebo First (Type: EXPERIMENTAL): Started on placebo, 3 week washout, start exenatide

Based on this trial design, predict the completion outcome and termination type (if applicable).